Prostate treatment could double cancer survival

27th April 2011

A single pill could be the answer to doubling the survival rate of prostate cancer, if new research is correct.

A study by Dr Roberto Pili has seen "quite promising" results from a one-a-day pill aimed at disrupting the formation of blood cells to the tumour, and improving the body's immune response to the cancer.

The cancer treatment, which is made from biologic agent tasquinimod, has been developed as an option for people who have been through other treatments which have failed. It has been proven effective whether the cancer has remained in the prostate or spread further in the body.

It is still in the trial stages, but the results so far have been pleasing, said Dr Pili, professor of oncology at Roswell Cancer Institute in Buffalo, New York.

He added: "The idea is to treat prostate cancer as a chronic disease. Hopefully, it's going to continue to work."

Prostate cancer is the most common cancer among men in the UK. Almost 40,000 men are diagnosed with the disease every year. It mainly affects men over the age of 50.

Posted by Edward Bartel

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

 

Find a treatment, test or scan available at:

or

Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.

or

Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...

Categories

Urology

© Spire Healthcare Group plc (2016)